News

Novartis fails in late-stage trial for Cosentyx in giant cell arteritis
Novartis (NVS) stock slips as the company's anti-inflammatory agent Cosentyx fails primary goal in a Phase 3 trial for giant ...
Novartis Update on Phase III GCAptAIN Study of Cosentyx in Giant Cell Arteritis
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...
Novartis's Cosentyx Fails to Meet Primary Goal at Late-Stage Trial
The pharmaceutical company said Thursday the drug did not meet its primary endpoint of sustained remission after 52 weeks of use in a phase three trial. Novartis said it will complete a full ...
Novartis and Cannes Can: Diversity Collective Team Up To Address Health Disparities
The forum came at time when there appears to be little health messaging at the federal level.
NJBIZ5d
EXCLUSIVE: Vamos Racquets brings padel, pickleball to former Novartis campus (updated)
Vamos Racquets will open in East Hanover with padel, pickleball, fitness, coworking and more at the former Novartis campus ...
Contract Pharma5d
ProFound Therapeutics Inks $750M+ Deal with Novartis
ProFound Therapeutics, a company pioneering the expanded human proteome to develop medicines, has announced a four-year ...
Novartis on Track for Record High Close — Data Talk
Novartis AG Sponsored ADR (NVS) is currently at $120.93, up $0.92 or 0.77% --Would be new all-time closing high (Based on available data back to Dec. 24, 1996) --Would be the first record close since ...